Q3 2024 Earnings Call Transcript November 7, 2024 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0 ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

More than a third of 100 hospitals analyzed by the HHS' Office of Inspector General did not post machine-readable pricing ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...

Mary Riordan, Senior Counsel at the US Health and Human Services Office of Inspector General (HHS-OIG) provided significant ...

The review of Minnesota-based Optum’s business practices by the Mississippi Board of Pharmacy indicated that the company paid independent pharmacies in Mississippi rates lower than chains and ...

Pharmacy Benefit Managers are the middlemen who manage virtually all prescriptions written in the U.S. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Novo Nordisk reports strong sales of Wegovy, propelling shares up 9%. Despite supply constraints, volumes are expected to ...